Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.10 -3.4%	$2.16	$1.11 ▼ $17.88	$39.95M	1.62	756,505 shs	440,443 shs
ATNF 180 Life Sciences	$0.83 -4.3%	$1.01	$0.66 ▼ $17.75	$4.73M	0.23	798,622 shs	26,480 shs
ELEV Elevation Oncology	$0.36 -5.9%	$0.35	$0.22 ▼ $3.28	$21.46M	1.43	1.50 million shs	7.89 million shs
EQ Equillium	$0.31 -9.0%	$0.38	$0.27 ▼ $1.50	$11.07M	1.94	438,811 shs	232,122 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-3.19%	-19.75%	-13.39%	+27.42%	-63.42%
ATNF 180 Life Sciences	-4.27%	-3.96%	-20.77%	-19.42%	-45.75%
ELEV Elevation Oncology	-5.90%	-4.91%	+19.77%	+39.35%	-84.58%
EQ Equillium	-8.96%	-5.17%	-17.47%	-23.53%	-53.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.09 of 5 stars	3.5	1.0	2.3	1.7	0.6
ATNF 180 Life Sciences	1.0403 of 5 stars	0.0	5.0	2.6	0.0	0.6
ELEV Elevation Oncology	2.2053 of 5 stars	3.0	2.0	3.3	1.7	0.6
EQ Equillium	2.3837 of 5 stars	3.2	2.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$30.25	1,343.23% Upside
ATNF 180 Life Sciences	0.00	N/A	N/A	N/A
ELEV Elevation Oncology	2.00	Hold	$3.39	834.51% Upside
EQ Equillium	2.33	Hold	$3.00	867.74% Upside

Current Analyst Ratings Breakdown

Latest ATNF, ANVS, ELEV, and EQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/11/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/10/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
4/24/2025	ATNF 180 Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	$2.91 per share	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.02 per share	N/A
EQ Equillium	$41.10M	0.27	N/A	N/A	$0.54 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
ATNF 180 Life Sciences	-$6.17M	N/A	0.00	∞	N/A	N/A	-147.32%	-76.99%	8/11/2025 (Estimated)
ELEV Elevation Oncology	-$44.49M	-$0.82	N/A	N/A	N/A	N/A	-74.68%	-48.14%	8/5/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.39	N/A	N/A	N/A	-19.62%	-74.34%	-46.75%	8/6/2025 (Estimated)

Latest ATNF, ANVS, ELEV, and EQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATNF 180 Life Sciences	N/A	-$0.67	N/A	-$0.67	N/A	N/A
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ATNF 180 Life Sciences	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
ATNF 180 Life Sciences	N/A	1.02	1.02
ELEV Elevation Oncology	0.67	19.40	19.40
EQ Equillium	N/A	2.70	2.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
ATNF 180 Life Sciences	4.07%
ELEV Elevation Oncology	83.70%
EQ Equillium	27.05%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
ATNF 180 Life Sciences	0.17%
ELEV Elevation Oncology	8.10%
EQ Equillium	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
ATNF 180 Life Sciences	7	5.70 million	5.69 million	No Data
ELEV Elevation Oncology	40	59.22 million	54.43 million	Optionable
EQ Equillium	40	35.72 million	24.43 million	Not Optionable

ATNF, ANVS, ELEV, and EQ Headlines

Recent News About These Companies

Equillium, Inc. (EQ) stock price, news, quote & history - Yahoo Finance

June 26 at 10:11 PM | nz.finance.yahoo.com

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

June 14, 2025 | medindia.netM

Equillium expands equity incentive plan by 1.78 million shares

May 24, 2025 | investing.com

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025 | finance.yahoo.com

Equillium advancing new AhR modulator

May 3, 2025 | bioworld.comB

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025 | finance.yahoo.com

Blood Cancer Data Ignore Sex; Cancer Biosimilars Take Off; Mixed Prevention News

April 26, 2025 | msn.com

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

April 25, 2025 | markets.businessinsider.com

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

April 25, 2025 | markets.businessinsider.com

FDA declines itolizumab accelerated approval, says Equillium

April 25, 2025 | thepharmaletter.comT

Equillium shares fall following FDA feedback

April 24, 2025 | in.investing.com

Equillium Announces Feedback from the U.S. Food and Drug Administration

April 24, 2025 | finance.yahoo.com

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 1, 2025 | zacks.com

The week in pharma: action, reaction and insight – week to March 28

March 30, 2025 | thepharmaletter.comT

Equillium downgraded to Market Perform from Outperform at Leerink

March 29, 2025 | markets.businessinsider.com

Equillium reports Q4 EPS (16c) vs. (7c) last year

March 28, 2025 | markets.businessinsider.com

Equillium reports EQUATOR study did not improve complete, overall response rates

March 28, 2025 | markets.businessinsider.com

Equillium Full Year 2024 Earnings: Beats Expectations

March 28, 2025 | finance.yahoo.com

Equillium says graft-versus-host drug fails Phase 3, stock dives

March 27, 2025 | endpts.comE

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27, 2025 | curetoday.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNF, ANVS, ELEV, and EQ Company Descriptions

Annovis Bio NYSE:ANVS

$2.10 -0.07 (-3.41%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$2.13 +0.03 (+1.62%)

As of 06/27/2025 07:15 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

180 Life Sciences NASDAQ:ATNF

$0.83 -0.04 (-4.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.84 +0.01 (+0.84%)

As of 06/27/2025 05:46 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

Elevation Oncology NASDAQ:ELEV

$0.36 -0.02 (-5.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.01 (+3.78%)

As of 06/27/2025 07:56 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Equillium NASDAQ:EQ

$0.31 -0.03 (-8.96%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.32 +0.01 (+2.26%)

As of 06/27/2025 07:50 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time